What is the difference between tirzepatide and semaglutide?
Key Takeaways
- Tirzepatide activates two hormone receptors (GIP and GLP-1) while semaglutide activates one, and trials show greater average weight loss with tirzepatide
- Rapid weight loss on either medication can cause facial volume loss, commonly called Ozempic face
- The right choice depends on your health history, tolerance, and goals, and should be made with a qualified physician
As weight loss medications become more effective, patients are asking a sharper question: not just how much weight they can lose, but how those changes will reshape their overall appearance. The tirzepatide vs semaglutide conversation has moved past a clinical readout; it is now a decision about how the body and the face transform over time.
Both medications belong to a newer generation of injectable therapies that regulate appetite and metabolism. They share a foundation, but their mechanisms and outcomes diverge in ways that matter clinically and aesthetically.
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Receptors | GLP-1 | GLP-1 and GIP |
| Average total body weight loss in trials | About 15 percent at 68 weeks | About 21 percent at 72 weeks on the highest dose |
| Dosing | Weekly injection, stepped titration | Weekly injection, stepped titration |
| Titration length to full dose | 16 to 20 weeks | 20 to 24 weeks |
| Most common side effects | Nausea, constipation, reflux | Nausea, diarrhea, reduced appetite |
| Facial volume loss risk | Present at any rapid rate of loss | Present, and often sooner given the steeper loss curve |
Weight loss figures come from the STEP 1 and SURMOUNT-1 trials, both published in the New England Journal of Medicine. Side effect profiles follow the FDA prescribing information for each drug.